Novo Nordisk Invests €400m in Irish Factory

Novo Nordisk, a prominent pharmaceutical company, is set to manufacture an oral tablet version of its popular weight-loss drug, Wegovy, at its facility in Athlone, County Westmeath, Republic of Ireland. This initiative involves a substantial investment of over €400m (£350m) to enhance the existing factory, marking a significant commitment to Ireland and its workforce. Construction for this expansion is already underway and is anticipated to be completed by 2028.

The Athlone plant will focus on producing the tablet form of Wegovy specifically for markets outside of the United States. This development comes as oral versions of such appetite-suppressing drugs gain traction, with US approval secured earlier this year. The company's investment underscores the strategic importance of its Irish operations amidst increasing competition in the lucrative weight-loss drug sector.

This expansion positions Novo Nordisk to meet growing global demand for its treatments. It also highlights Ireland's role as a key pharmaceutical manufacturing hub. The company's rival, Eli Lilly, also maintains a significant manufacturing presence in Ireland, producing active ingredients for its own weight-loss medications, further solidifying the country's importance in this medical field.